CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study
Date
2023-10-31
Authors
Neale, Isabel
Ali, Mohammad
Kronsteiner, Barbara
Longet, Stephanie
Abraham, Priyanka
Deeks, Alexandra S.
Brown, Anthony
Moore, Shona C.
Stafford, Lizzie
Dobson, Susan L.
Version
Published version
OA Version
Citation
I. Neale, M. Ali, B. Kronsteiner, S. Longet, P. Abraham, A.S. Deeks, A. Brown, S.C. Moore, L. Stafford, S.L. Dobson, M. Plowright, T.A.H. Newman, M.Y. Wu, Crick COVID Immunity Pipeline, E.J. Carr, R. Beale, A.D. Otter, S. Hopkins, V. Hall, A. Tomic, R.P. Payne, E. Barnes, A. Richter, C.J.A. Duncan, L. Turtle, T.I. de Silva, M. Carroll, T. Lambe, P. Klenerman, S. Dunachie, PITCH Consortium. 2023. "CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study." mBio, Volume 14, Issue 5, pp.e0121223-. https://doi.org/10.1128/mbio.01212-23
Abstract
Defining correlates of protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine breakthrough infection informs vaccine policy for booster doses and future vaccine designs. Existing studies demonstrate humoral correlates of protection, but the role of T cells in protection is still unclear. In this study, we explore antibody and T cell immune responses associated with protection against Delta variant vaccine breakthrough infection in a well-characterized cohort of UK Healthcare Workers (HCWs). We demonstrate evidence to support a role for CD4+ and CD8+ T cells as well as antibodies against Delta vaccine breakthrough infection. In addition, our results suggest a potential role for cross-reactive T cells in vaccine breakthrough.
Description
License
Copyright © 2023 Neale et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.